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Background. Antiretroviral pharmacology in seminal plasma (SP) and rectal tissue (RT) may provide insight
into antiretroviral resistance and the prevention of sexual transmission of human immunodeficiency virus (HIV).
Saliva may be of utility for noninvasively measuring adherence.
Methods. A pharmacokinetic study was performed in 12 HIV-negative men receiving maraviroc 300 mg twice
daily for 8 days. Seven time-matched pairs of blood plasma (BP) and saliva samples were collected over 12 h on day 1
(PK1) and days 7 and 8 (PK2). One RT sample from each subject was collected during PK1 and PK2. Two SP samples
were collected from each subject during PK1, and 6 SP samples were collected from each subject during PK2.
Results. SP AUCs were 50% lower than BP. However, protein binding in SP ranged from 4% to 25%,
resulting in protein-free concentrations .2-fold higher than BP. RT AUCs were 7.5- to 26-fold higher than BP.
Maraviroc saliva AUCs were 70% lower than BP, but saliva concentrations correlated with BP (r2 5 0.58).
Conclusions. More pharmacologically available maraviroc was found in SP than BP. High RT concentrations
are promising for preventing rectal HIV acquisition. Saliva correlation with BP suggests that this may be useful for
monitoring adherence.
Clinical Trials Registration. NCT00775294.
Between 2004 and 2007, the incidence of HIV/AIDS
increased 15% in the United States [1]. In men who
have sex with men (MSM), this increase was 26%. The
highest risk of HIV acquisition occurs with receptive
anal intercourse [2], as the rectal mucosa is rich in
lymphoid tissue and has a thin epithelium [3].
Data from the Phase III CAPRISA 004 study, which
evaluated a topical tenofovir gel formulation for pre-
vention of HIV acquisition in women, not only provide
the proof of concept for microbicides but also further
evidence that antiretroviral-based prevention strategies
can be effective [4]. To date, topical rectal microbicide
and vaccine trials have not demonstrated compelling
benefit in HIV prevention; therefore, investigations using
orally administered antiretrovirals are still necessary [5,
6]. Antiretrovirals can be used for both primary and
secondary HIV prevention. Primary prophylaxis prevents
acquisition of HIV in an uninfected individual, and sec-
ondary prophylaxis reduces the likelihood of an HIV-
infected individual transmitting HIV. Primary prevention
can be further separated into pre-exposure prophylaxis
(PrEP) and post-exposure prophylaxis (PEP). PrEP re-
quires administering antiretrovirals to at-risk individuals
prior to a potential HIV exposure, and PEP involves
administering antiretrovirals to an HIV-negative in-
dividual after a suspected exposure to HIV. Measuring
antiretroviral exposure in rectal tissue could assist in se-
lecting drugs and dosing regimens for PrEP and PEP.
HIV transmission modeling has correlated increasing
concentrations of HIV RNA in semen to an increasing
probability of infection [7]. Despite suppression of HIV
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RNA in blood, HIV RNA can still be detected in genital secre-
tions of up to 8% of HIV-infected men on antiretroviral therapy
[8]. Using selected antiretrovirals to target the genital tract and
decrease HIV replication in genital secretions has implications
for transmission. If semen drug concentrations are high enough,
it might be also be possible to deliver a protective amount of
drug to a receptive mucosal surface through this route [9].
The ability to monitor drug concentrations has allowed
clinicians to make important decisions regarding adherence to
antiretroviral regimens. Under most conditions, concentration
monitoring requires a blood sample. Saliva sampling has been
explored as an alternative to blood sampling and has the
advantages of being less invasive and requiring less processing
time upon collection [10].
Within the female genital tract, the CCR5 antagonist
maraviroc (Celsentri/Selzentry; Pfizer, Inc) achieves very high
exposure [11]. The current study was designed to understand
exposure of maraviroc in the saliva, seminal fluid, and rectal
tissue following single and multiple doses.
METHODS
Study Design and Subject Selection
This 8-day, open-label, pharmacokinetic (PK) study in healthy
HIV-negative male volunteers was conducted between July 2008
and May 2009 at the University of North Carolina at Chapel
Hill (UNC). Maraviroc tablets and funding for this investigator-
initiated study were provided by Pfizer, Inc. The UNC Bio-
medical Institutional Review Board approved the protocol. All
subjects provided written informed consent.
Screening procedures occurred within 42 days of maraviroc
dosing. Subjects were eligible to participate if they were healthy
males 18–49 years of age having a body mass index between 18
and 30 kg/m2, with intact genital and gastrointestinal tracts.
Subjects were excluded if they had a history of regular alcohol
consumption, were currently smoking more than 5 cigarettes
per day, had a positive urine drug screen, or had a currently
active sexually transmitted disease. Subjects were screened for
gonorrhea, chlamydia, trichomonas, syphilis, herpes simplex
virus- 2, hepatitis B and C, and HIV. All testing was performed
in the McLendon Laboratories of UNC Hospitals and in the
UNC Sexually Transmitted Diseases Cooperative Research
Center Microbiology Core Lab.
Subjects were excluded for any clinically significant abnor-
mality in the laboratory results or physical examination deemed
by the study physician to increase subject risk or compromise
study results. Twelve-lead electrocardiogram (ECG) testing was
performed per standard Pfizer protocol for healthy volunteer
studies with maraviroc, and subjects were excluded if they
exhibited a QTc .450 ms [12, 13]. All medications and
herbal supplements, with the exception of acetaminophen (up to
1g/day), had to be discontinued at least 7 days prior to study
drug dosing until study completion. Subjects were instructed to
abstain from all sexual activity and use of intra-rectal products
72 h prior to dosing until study discharge.
Safety laboratory monitoring was performed on days -1, 3 or
4, 6, and follow-up. A full physical examination was performed
at screening and at follow-up, and brief physical examinations
were performed on days -1 and 6. Urine toxicology screening
was performed at screening and on days -1 and 6. Orthostatic
blood pressure and pulse measurements were performed at
admission and discharge of each visit. ECGs were repeated on
days -1, 6, and at follow-up.
Study Visits
Subjects received maraviroc 300 mg orally twice daily on days
1–7 and a single 300-mg dose on the morning of day 8. Subjects
followed a low fiber diet for 3 days prior and a clear liquids diet
the afternoon prior to the rectal tissue (RT) biopsies, which were
performed via flexible sigmoidscopy. Subjects were admitted the
evening before day 1 to the UNC TraCS Clinical Translational
Research Center (CTRC) and provided a baseline semen sample.
Subjects fasted for 2 h before and 4 h after dosing on days 1, 7,
and 8. On day 1, paired blood plasma (BP) and saliva samples
were obtained at pre-dose, 1, 2, 3, 6, 8, and 12 h after the first
dose. Each subject collected 2 semen specimens that time-
matched 2 of the 6 post-dose BP samples with a total of 4
subjects assigned to each time point. A single RT biopsy was
obtained time-matching one post-dose BP sample with a total of
2 subjects assigned to each time point. Subjects recorded the
time of dosing at home and were instructed to take doses
without regard to meals. Subjects returned to the CTRC for
trough BP and SP sampling and adherence monitoring on days 3
and 5 or on days 4 and 6. Subjects were readmitted to the CTRC
in the evening of day 6. On days 7 and 8, BP, saliva, and RT PK
sampling identical to day 1 were performed. However, subjects
collected 6 semen specimens over days 7–8 that matched the BP
sampling time-points. Subjects were discharged after the 12-h
PK sample collection on day 8 and returned for safety evalua-
tions 7–10 days after the last dose of maraviroc.
Sample Collection and Processing
Whole blood was obtained using K2EDTA collection tubes (BD
Diagnostics) and centrifuged at 1700 g at 5C for 10 minutes.
Saliva samples were collected and stored without processing.
Whole semen samples were allowed to liquefy at room tem-
perature for at least 45 minutes prior to centrifugation at 2500 g
at 10C for 15 minutes. Ten single RT biopsies were collected
using Radial Jaw 4 Large Capacity Forceps (Boston Scientific),
pooled into a single cryovial, and snap frozen. Rectal biopsy
sites were rinsed with a solution containing simethicone 40 mg
(simethicone oral suspension 40 mg/0.6 mL, Major Pharma-
ceuticals) diluted in 500 mL sterile water for irrigation prior to
collection. All specimens were stored at 280C until analysis.
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Maraviroc was extracted from 100 lL BP, 200 lL saliva, and
200 lL SP using solid phase extraction (SPE) with Bond Elut-
Varian C-18, 100 mg, 1CC cartridges. For saliva and SP, ace-
tonitrile protein precipitation was performed prior to SPE.
Maraviroc was extracted from 25 mg of homogenized rectal
tissue by acetonitrile protein precipitation. Extraction recoveries
were $85% for RT and BP and $74% for all other matrices.
Variability in extraction recovery was ,10%.
SP protein binding was determined by incubating 300 lL of
SP pooled by subject from PK2 in duplicate at 37C for 16 h
in rapid equilibrium dialysis cartridges (Rapid Equilibrium
Dialysis Device System, Thermo Scientific; Thermo Scientific
RED Device Inserts, Thermo Scientific Part No: 89809; reusable
Teflon base plate, Thermo Part No: 89811), followed by protein
precipitation. Validation of equilibrium dialysis was performed
according to FDA guidelines [14].
Maraviroc concentrations were analyzed using validated
methods on an Agilent 1200 series High Performance Liquid
Chromatography System and an 1100 MSD (Agilent Technol-
ogies, New Castle, Delaware). The Agilent 1100MSD instrument
was used in positive ESI spray mode, with a source temperature
of 350C. Analytes were separated on a Zorbax Eclipse XDB
column (4.6 3 50 mm, 1.8 lm) with a frit (4.6 mm, 0.2 lm)
(Agilent Technologies) using a gradient mobile phase method.
The m/z was 514.3 for maraviroc and 309.1 for the internal
standard alprazolam. The quantification ranges of the assays
were 1–1000 ng/mL for BP, saliva, and SP, and 7-7000 ng/g for
rectal tissue. Intra- and inter-day accuracy and precision was
#15% and #10%, respectively, for all matrices. All methods
were validated as mandated by the industry guidance set by the
US DHHS, FDA, and CDER [14].
Data Analysis
BP, saliva, SP, and RT pharmacokinetic parameters were esti-
mated using noncompartmental methods (Phoenix WinNonlin;
Pharsight). The maximum concentration (Cmax) was de-
termined visually, and Tmax was defined at Cmax. Exact sample
collection times were used in the analysis. The area under the
plasma concentration-time curve within the dosing interval
(AUC12h) was estimated using the log-linear trapezoidal
method, and visual curve stripping was performed for estima-
tion of the terminal elimination slope. C12hb was obtained from
the intermediate analysis output calculating AUC12h. For PK2
individual time concentration profiles were created using the six
samples collected on days 7 and 8, and by supposition, the
concentration at 12 h post-dose was used as the concentration at
time zero. Previous investigations have determined that sam-
pling frequency does not affect SP concentrations of anti-
retrovirals [15]. To estimate SP PK parameters for PK1, and RT
PK parameters for PK 1 and PK2, a composite approach was
used by analyzing geometric mean concentration data. Com-
posite profiles for PK1 SP, PK1 RT and PK2 RT were created
using geometric mean concentrations and times at each time
point, and samples were grouped using the closest nominal time.
A rectal tissue density of 1.04 g/mL was used to convert ng/g to
ng/mL [16]. To compare SP and RT exposure to BP, SP:BP and
RT:BP AUC12h ratios were calculated for days 1 and 7/8. To
describe multidose accumulation in BP, SP, and RT, PK2:PK1
AUC12h ratios were calculated.
Descriptive statistics were generated by SAS Institute, Inc
software version 9.1.3 (Cary, NC). Demographic data and
pharmacokinetic parameters are presented as median (range).
Geometric mean ratios (GMR) with 90% confidence intervals
(90% CI) are presented for PK1 saliva vs BP, PK2 saliva vs BP,
and PK2 SP vs BP. For the ratios that included a composite
profile (PK1 SP vs BP, PK1 RT vs BP, and PK2 RT vs BP), the
composite parameter value was divided by the corresponding
geometric mean BP. Spearman correlation was performed across
all paired data.
The percent of protein-unbound maraviroc was calculated by
subtracting the percent protein-bound from 100%. The
unbound trough concentration of drug in SP was calculated
conservatively: the minimum C12h in SP from PK2 was
multiplied by the minimum percent protein-unbound derived
from the RED cartridge analytical method. The protein-
unbound GMRs were calculated similarly by using the reported
unbound fraction in BP (24%) [17].
RESULTS
Subject Demographics, Disposition, and Safety
Thirty-two men screened for this study: 14 were enrolled, and
12 completed. Of the 14 subjects, one subject withdrew due
to grade 2 arthralgia on day 3, and the second subject was
withdrawn due to positive urine toxicology for amphetamines.
These 2 subjects did not contribute demographic or PK data.
Median (range) age of the 12 participants was 22 (20–42) years,
weight was 81.3 (62–92.4) kg, and body mass index was 25.1
(20.2–29.1) kg/m2. Eight of the 12 subjects were Caucasian/
white, 3 were African American/black, and 1 identified as mixed
race (African/European).
Subjects tolerated the study medication well. Most adverse
events (AEs) were mild in severity, and no serious AEs were
reported. The most frequently reported AEs were headache
(25%), GI disturbance (25%), dizziness (17%), and dry mouth
(17%). One subject reported mild joint pain and gum sensitivity
that resolved by follow-up. Three subjects were unable to pro-
duce a semen specimen within the allotted time near the end of
the multiple dose study visit, one of whom reported testicular
pain (related to sampling; unrelated to maraviroc) and missed
2 samples. RT sampling was well tolerated. Three subjects
reported spotting on toilet tissue and a small amount of blood
on stool immediately following the procedure, resolving within
a few hours.
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BP, Saliva, Semen and Rectal Tissue Pharmacokinetics
Figures 1 and 2 depict the BP, saliva, SP, and RT concentrations
for all subjects at day 1 and day 7/8, respectively. For SP PK1, 3
samples were collected for T 5 1, 5 for T 5 2, 3 T 5 3, and 4
for T 5 6, T 5 8, and T 5 12. For SP PK2, 3 subjects were
unable to collect all 6 samples. In 2 of these subjects, the terminal
elimination slope could not be modeled, and therefore their PK
parameters could not be resolved. For RT PK1, 2 samples were
collected for each time point. For RT PK2, 2 samples were
collected at all time-points, with the exception of 1 collected at
T 5 6 and 3 collected at T 5 8. Maraviroc was detected in all
biological matrices after the first dose. RT concentrations
exceeded BP concentrations at all time-points on both days 1
and 7/8. On day 1 SP concentrations were lower than BP up to 6
h post-dose; after 6 h, they were similar. Saliva concentrations
remained detectable throughout the dosing interval in all
collected post-dose samples, but concentrations were lower than
BP. On day 7/8, similar SP, BP, and saliva PK were observed.
Spearman rank correlation coefficients indicated that BP
concentrations correlated with saliva (rho 5 0.76, P , .0001)
and SP (rho 5 0.74, P , .0001). BP concentrations did not
correlate with rectal tissue (rho 5 0.21, P 5 .33). All BP, saliva,
and SP C12h samples collected on days 3–6 had detectable
maraviroc concentrations suggesting that subjects were
compliant with the study drug regimen (data not shown).
Table 1 summarizes the PK parameters for each matrix.
After single and multiple doses, median AUC12h, Cmax, and C12h
were highest in RT, and Cmax was higher in BP than saliva
and SP. For PK1 and PK2, AUC12h and C12h were lower in saliva
than BP and SP.
Table 2 summarizes accumulation ratios (PK2:PK1) for each
matrix over time. The maraviroc accumulation ratio in BP was
1.4, in saliva was 1.7, in SP was 1.6, and in RT was 4.9. Maraviroc
exposures in SP, saliva, and rectal tissue were compared with BP
using the following ratios: SP:BP, SAL:BP, RT:BP. For PK1, the
saliva C12h and AUC12h were 51% and 72% lower than in BP,
respectively. After PK2, the saliva C12h and AUC12h were 60%
and 66% lower than in BP. SP PK1 C12h and AUC12h were 2%
and 55% lower than in BP, respectively. SP PK2 C12h and
AUC12h were 32% and 44% lower than in BP, respectively. For
rectal tissue, the PK1 C12h and AUC12h were 51.7 and 7.5 times
higher than in BP, respectively. The rectal tissue PK2 C12h and
AUC12h were 87.6 and 26.2 times higher, respectively, than in
BP.
SP protein binding ranged from 3.6% to 24.8% with a median
of 8.9%. The protein binding in blood plasma is reported to be
76% [17]. The unbound trough concentration (C12h) in SP was
conservatively calculated to be at least 28-fold higher than the
protein-free IC90 for maraviroc (14.2 ng/mL vs 0.5 ng/mL).
Although total drug concentrations are lower in SP compared
with BP, protein-free trough concentrations in SP are 2.1-fold
higher than protein-free trough concentrations in BP, and
protein-free exposures in SP are 1.8-fold higher than protein-
free exposures in BP.
DISCUSSION
R5 HIV is responsible for .95% of sexually transmitted new
infections [18, 19]. Such viruses require CCR5 binding for entry
and infection of mononuclear cells. Since maraviroc blocks
CCR5 binding, its use could be a significant addition to
Figure 1. Maraviroc concentrations after a single dose (PK1)-geometric
mean (90%CI) maraviroc concentrations in rectal tissue (diamonds), BP
(squares), SP (circles), and saliva (triangles) on study day 1. Times are
staggered to improve visualization of the data. Geometric mean sampling
times are used for SP and RT.
Figure 2. Maraviroc concentrations after multiple doses (PK2)-maraviroc
concentrations in rectal tissue (diamonds) and SP (circles) on study day 7
and 8 and in BP (squares) and saliva (triangles) on study day 8. Times are
staggered to improve visualization of the data. Geometric mean sampling
times are used for SP and RT.
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antiretroviral prevention strategies. Additionally, maraviroc
carries relatively few adverse events that occur in low frequency,
making it a potentially favorable candidate [17]. This study was
designed to assess the pharmacologic plausibility of using orally
dosed maraviroc for primary (RT) and secondary (SP) pre-
vention in men and to explore alternate methods for clinical
trials adherence measures (saliva).
Understanding antiretroviral RT pharmacokinetics is essen-
tial in developing appropriate strategies to prevent rectal
acquisition of HIV. Compared to BP, RT exposures of
maraviroc were 7.5 times higher after a single dose and 26 times
higher after multiple doses. Currently, the concentration of
maraviroc needed to prevent HIV is not known. However,
colorectal tissue explant data demonstrate that a maraviroc
concentration of 500 ng/mL prevented 85% of infections after
incubating the tissue for at least 3 h [20]. Our data show that
a single maraviroc dose achieves an average concentration
(AUC12h/12 h) 2-fold higher than this concentration. This quick
penetration of maraviroc into the rectal tissue may be due to
a highly vascularized mucosa and interstitial trapping. Our
findings are also consistent with radio-imaging studies in ro-
dents which demonstrated 40–50 fold higher exposures of radio-
labeled maraviroc in the gastrointestinal tract (including GALT
lymphatics) when administered intravenously [21]. The accu-
mulation in RT after multiple dosing is 4 times greater than in
BP (4.1 vs 1.29). This suggests that mechanisms other than
distribution from BP are responsible for this accumulation. We
hypothesize that these high exposures may in part be due to the
elimination of maraviroc (30% of the dose is fecally eliminated)
and mucus trapping of drug [22]. The use of composite profiles
in this study was employed due to the nature of sampling lim-
itations for SP after a single dose and RT. Geometric means of
the concentrations and times for these composites best repre-
sented the data visually compared with means or medians.
Table 1. Median (range) Maraviroc Pharmacokinetic Parameters in Blood Plasma, Saliva, Seminal Plasma, and Rectal Tissue After
Single (PK1) and Multiple Dosing (PK2)
Blood Plasma Saliva Seminal Plasma Rectal Tissue
PK1 (Single dose)
Cmax (ng/mL or ng/g) 412 (155-690) 82.4 (37.7–199) 89.0
a 1399a
Tmax (h) 1.6 (1.0–6.0) 3.0 (1.0–6.0) 2.2
a 3.3a
C12h (ng/mL or ng/g) 20.5 (7.2–51.8) 11.7 (3.9–37.2) 22.3
a 1186a
AUC12h (ng*h/mL or ng*h/g) 1680 (510–3015) 483 (198–943) 700
a 11622a
PK2 (Multiple Dose)
Cmax (ng/mL or ng/g) 522 (282–1402) 186 (58.6–325) 180 (90.2–664)
b 7119a
Tmax (h) 3.0 (1.0–6.0) 3.0 (1.0–6.1) 3.5 (2.4–6.3)
b 1.3a
C12h (ng/mL or ng/g) 52.4 (22.8–102) 24.3 (7.3–42.7) 38.2 (18.9–74.9)
b 4466a
AUC12h (ng*h/mL or ng*h/g) 2086 (1477–4372) 827 (252–1298) 1123 (633–2087)
b 57326a
NOTE. PK1 seminal plasma, PK1 rectal tissue, and PK2 rectal tissue data were analyzed as composite concentration-time profiles. Blood plasma and saliva
parameters for PK2 were calculated using data from study day 8. Seminal plasma (N 5 10) and rectal tissue parameters for PK2 were calculated using data from
study days 7 and 8. AUC12h and C12h could not be determined for 2 subjects’ PK2 seminal plasma due to missing samples and were excluded.
a composite profiles.
b N 5 10.
Table 2. Relative Exposure of Maraviroc in Saliva, Seminal, and Rectal Tissue to Blood Plasma and Day 8:Day 1 Accumulation Ratios
Blood Plasma Saliva Seminal Plasma Rectal Tissue
PK1 (Single Dose)
C12h ref 0.49 (0.35–0.68) 0.98
a 51.75a
AUC12h ref 0.28 (0.23–0.35) 0.45
a 7.48a
PK2 (Multiple Dose)
C12h ref 0.40 (0.29–0.54) 0.68 (0.48–0.95) 87.55
a
AUC12h ref 0.34 (0.27–0.43) 0.56 (0.44–0.70) 26.24
a
PK2 : PK1
C12h 2.23 (1.78–2.78) 1.81 (1.37–2.38) 1.57
a 3.77a
AUC12h 1.41 (1.18–1.68) 1.74 (1.38–2.19) 1.65
a 4.93a
NOTE. C12h and AUC12h ratios for saliva to BP (Saliva:BP), SP to BP (SP:BP) (N5 10), and rectal tissue to BP (RT:BP). A tissue density of 1.04 g/mL was used to
compare rectal tissue concentrations to BP concentrations. Accumulations ratios comparing PK2 (day 8) C12h and AUC12h to PK1 (day 1) C12h and AUC12h. Geometric
mean ratios (90% CI) are presented, except for parameters based on composite profiles.
a composite profile used.
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This study was not designed to evaluate the terminal elimination
of maraviroc in the rectal mucosa. This study characterized
the pharmacokinetics of the unperturbed rectal mucosa. Bowel
preparations were not used prior to the biopsy procedure, since
hyperosmolar enemas can shift a significant amount of water
into the lumen of the colon and cause epithelial sloughing [23].
However, future studies assessing the impact of bowel
preparations will be important, as they can be commonly (up to
60% of MSM) used prior to anal intercourse [24] and
may increase the risk of HIV transmission [2]. A study by
Hendrix et al is ongoing to better assess preferences and the
effects of various enemas on the integrity of the rectal mucosa
(http://clinicaltrials.gov/ct2/show/NCT00696618).
Previous data in the female genital tract demonstrated that
maraviroc concentrated 3-fold in cervicovaginal fluid (CVF),
and protein binding in CVF was 10% of that in BP [11]. Overall,
this study found that total SP concentrations were lower
than BP. Maraviroc is the first antiretroviral to demonstrate
a discrepancy between male and female genital tract exposures.
Although the explanation for this finding is not unknown, these
data caution against extrapolating genital tract pharmacology
data generated in one sex to the opposite sex.
Our finding of total maraviroc exposure in SP being lower
than BP is consistent with other antiretrovirals based on BP
protein binding. A correlation can be visualized between the
relative exposures of antiretrovirals (as measured by SP:BP AUC
ratios) and BP protein binding (Figure 3). As BP protein binding
decreases, there is greater amount of protein-unbound drug
available to distribute into physiological compartments.
Approximately 76% of maraviroc is bound to albumin in BP,
leaving 24% available for pharmacologic activity. However,
albumin concentrations in SP are1/35 of that in BP [27]. This
investigation determined that unbound SP concentrations were
2-fold higher than BP concentrations, and at least 28-fold
higher than the protein-free IC90 for maraviroc (0.5 ng/mL). To
evaluate maraviroc’s role in secondary prevention, the ability of
maraviroc to fully suppress HIV replication in the male genital
tract will need to be confirmed in animal models or longitudinal
investigations in HIV-infected men.
Finally, saliva was investigated as a potential approach to
adherence testing. The AUC and C12h of maraviroc in saliva
were 30%, and 40%–50% of that of BP, respectively. Of the
biological matrices investigated, saliva concentrations correlated
with BP concentrations (rho 5 0.76, P , .001), suggesting
that saliva could be used for real-time adherence monitoring,
especially in prevention trials.
In summary, this is the first study to evaluate antiretroviral
exposure in the rectal mucosa, and the first to measure mar-
aviroc and its protein binding in SP. These data provide phar-
macologic plausibility of maraviroc’s use in primary and
secondary HIV prevention. The quick penetration and sustained
concentrations of maraviroc in the rectal mucosa are desirable
characteristics. The unbound concentrations in semen are
higher than in blood and could be effective in suppressing
R5 tropic HIV replication in the male genital tract. Future
investigations will determine if the concentrations in rectal
tissue and semen can prevent HIV acquisition and fully suppress
viral shedding. Saliva sampling is a feasible noninvasive method
of monitoring drug adherence. Despite intensive sampling and
scheduling challenges for multiple precisely timed rectal biopsies
and semen samples, our data demonstrate that these studies can
be performed efficiently and safely.
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